Quattro’s single focus is on helping healthcare companies accelerate growth. Since our founding, we have worked exclusively in biopharmaceuticals and medical technology, so we know the healthcare landscape very well. From Fortune 500 to early-stage, our client work has included assessing business development opportunities, identifying new growth paths, conducting due diligence, evaluating pricing and positioning, and many other strategic issues. In addition, we have worked extensively with some of the most highly respected, widely known biotech investors on Wall Street to analyze prospective and current investments and independently verify assumptions. We have a reputation for being exceptionally good at assessing the strategic, quantitative, and marketing implications of how and why physicians decide among different treatment options, including those that compete either directly or indirectly. Quattro has analyzed opportunities in oncology, cardiology, dermatology, neurology, immunology, nephrology, hematology, endocrinology, infectious diseases, orthopedic surgery, general surgery, radiology, gastroenterology, and many others. We dive deeply into the detailed aspects of competitive opportunities for investigational and commercially available drugs, devices, and diagnostics. This often includes, for example, clinical trial results, prevalence and incidence data, mechanisms of action, segmentations of disease pathophysiology and patient symptoms, patterns in physician referrals and decision-making, and more. We weave this in-depth understanding into rigorously quantitative market models that help predict growth, gauge sensitivities, and prioritize actions. Compared to our competitors, Quattro’s depth of experience delivers answers that are more pragmatic, insightful, and on-target. Lastly, our clients consistently tell us how much they appreciate our uniquely individualized attention: Quattro’s managing directors personally lead every client project.